Solid Biosciences Inc. Payments for Restructuring
Solid Biosciences Inc. (SLDB) reported Payments for Restructuring of $143.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-15.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsForRestructuring · last filed 2024-05-15
- Solid Biosciences Inc. payments for restructuring for the quarter ending 2024-03-31 was $143.00K.
- Solid Biosciences Inc. payments for restructuring for the quarter ending 2022-09-30 was $751.00K.
- Solid Biosciences Inc. payments for restructuring for the quarter ending 2022-06-30 was $728.00K.
- Solid Biosciences Inc. payments for restructuring for the quarter ending 2021-03-31 was $62.00K, a 93.56% decline year-over-year.
- Solid Biosciences Inc. payments for restructuring for fiscal 2020 was $1.88M.
| Period end | Payments for Restructuring 3 month | Payments for Restructuring 6 month | Payments for Restructuring 9 month | Payments for Restructuring 12 month |
|---|---|---|---|---|
| 2024-03-31 | $143.00K 10-Q · filed 2024-05-15 | |||
| 2023-12-31 | $3.67M 10-Q · filed 2024-05-15 | |||
| 2022-09-30 | $751.00K 10-Q · filed 2022-11-10 | $1.48M derived: sum of 2 quarters · filed 2022-11-10 | $1.48M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $728.00K 10-Q · filed 2022-08-11 | $728.00K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $62.00K 10-K · filed 2022-03-14 | $273.00K derived: sum of 2 quarters · filed 2022-03-14 | $519.00K derived: sum of 3 quarters · filed 2022-03-14 | $981.00K derived: sum of 4 quarters · filed 2022-03-14 |
| 2020-12-31 | $211.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $457.00K derived: sum of 2 quarters · filed 2022-03-14 | $919.00K derived: sum of 3 quarters · filed 2022-03-14 | $1.88M 10-K · filed 2022-03-14 |
| 2020-09-30 | $246.00K 10-Q · filed 2020-11-05 | $708.00K derived: sum of 2 quarters · filed 2020-11-05 | $1.67M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $462.00K 10-Q · filed 2020-08-06 | $1.43M 10-Q · filed 2020-08-06 | ||
| 2020-03-31 | $963.00K 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |